Nrx Pharmaceuticals Stock Earnings Reports

NRx reported a productive Q1 2026: major progress toward commercializing preservative-free ketamine (KETAFREE) with FDA review advancing, site reclassified to VAI, and initial commercial manufacturing initiated using blow-fill-seal (BFS) technology. Management expects to address ongoing U.S. ketamine shortages and positions KETAFREE as the first U.S.-manufactured preservative-free ketamine. The NRX-100 NDA is on track for Q2 submission and will combine >1,000 clinical trial patients with real-world evidence from ~65,000 patients via Osmind; FDA indicated willingness to consider RWE for approval. NRX-101 progressed with Module 3 filing and received FDA clearance for the MIND1 Phase IIb/III trial (400 patients) as an adjunct to accelerated TMS; the company expects nondilutive funding and military/academic partnerships. HOPE Therapeutics clinic network is expanding (5 clinics in Q1; 8+ expected by end of Q2) and integrating digital tools (EMOBOT) and TMS partnerships. The company acquired Geneuro assets (anti-HERV portfolio) to expand pipeline in neurological/autoimmune indications. Financially, NRx reduced net loss 74% YoY to ~$1.4M Q1; cash was $6.7M at quarter end, management expects runway through at least 2026 and has raised ~$7M post-quarter via ATM sales; the company is debt-free. Key investor considerations: near-term regulatory milestones for KETAFREE and NRX-100, potential commercial launch logistics and inventory (management plans ≥1M units in warehouse at launch), clarity/acceptance of RWE by FDA, funding runway and dilution risk depending on further financings, and upside from the MIND1 trial and Geneuro asset commercialization if clinical data/readouts are positive.